Paediatric Behçet’s disease presenting with recurrent papillitis and episcleritis: a case report

Fulvio Parentin1*, Loredana Lepore2, Ingrid Rabach2, Stefano Pensiero1

Abstract

Introduction: Behçet’s disease is a chronic multisystem vasculitis characterized by mucocutaneous, articular, neurological, gastrointestinal and ophthalmological lesions. Ocular involvement is mainly represented by recurrent uveitis, especially posterior uveitis; however, iridocyclitis, retinal and choroidal vasculitis, optic neuritis and retinal vascular occlusion can also occur.

Case presentation: A 12-year-old Caucasian boy with a history of recurrent buccal aphthosis and nonspecific gastrointestinal symptoms was admitted to our hospital with blurred vision associated with acute episcleritis and papillitis. The patient’s pathergy test was positive, suggesting a diagnosis of Behçet’s disease. Corticosteroid and cyclosporine therapy was started, but further episodes were noted in both eyes. The patient was then switched to intravenous infliximab, with complete resolution of the inflammation after the second infusion.

Conclusion: Episcleritis and papillitis should be added to the list of uncommon manifestations of pediatric Behçet’s disease. Infliximab is an effective, new therapeutic approach for Behçet’s disease that is refractory to the conventional corticosteroid and immunosuppressive therapy.
relapsed four times in the following six months in both eyes. The patient was therefore commenced on oral cyclosporine 100 mg twice daily, but another two episodes were noted, and the therapy was stopped after four months. He was then switched to endovenous infliximab, a chimeric anti-tumor necrosis factor-α (anti-TNF-α) monoclonal antibody, in an attempt to control the disease. Infusions of 5 mg/kg infliximab were administered at zero, two and six weeks and then at intervals of eight weeks. There was a remarkable response soon after the first infusion and a complete resolution of the inflammation after the second infusion. The patient remains well one year later and continues to enjoy remission on continued therapy with infliximab at intervals of eight weeks.

Discussion
Childhood-onset Behçet’s disease is uncommon, accounting for 3% to 7% of all cases [2]. Scleritis may be a harbinger of systemic autoimmune inflammatory diseases. Few publications have reported an association between Behçet’s disease and scleral inflammation, and only among adult patients. Episcleritis is a benign inflammation confined to the episcleral tissue; patients with episcleritis usually complain of mild pain. In 2004, Dursun et al. [3] reported a case of systemic Behçet’s disease with anterior necrotizing scleritis, lateral rectus myositis and recurrent retrobulbar optic neuritis. Nodular and diffuse scleritis is characterized by edema and injection in both the superficial and deep episcleral vessels, and pain is usually severe and deep-seated. Finally, scleromalacia perforans is a necrotizing scleritis, relatively asymptomatic and without inflammation. In 2005 Sakellariou et al. [4] reported the unique association between Behçet’s disease and scleromalacia perforans.

Optic neuritis is a rare manifestation of neuro-Behçet’s disease. A search of MEDLINE retrieved only one case report of inflammatory optic nerve involvement in the pediatric age group [5]. The diagnosis in children is difficult, as the disease is uncommon and clinically resembles other diseases, such as multiple sclerosis. Another important differential diagnosis is central venous sinus thrombosis, which is well described in Behçet’s disease and is usually characterized by severe headache and deterioration in general condition.

Infliximab, a chimeric monoclonal antibody to TNF-α, was developed and used to treat systemic inflammatory disorders such as rheumatoid arthritis and Crohn’s disease. Proinflammatory cytokines, including TNF-α, are
known to be elevated in active Behçet’s disease, suggesting that anti-TNF-α therapy might be effective. Clinically, significant improvement of various Behçet’s disease manifestations with infliximab therapy has been reported in the literature [6,7]. A recent study demonstrated that the effectiveness of infliximab on the ocular inflammation in Behçet’s disease correlates with the infliximab serum concentrations [8].

Conclusion
First, our report underlines that episcleritis and papillitis without uveitis should be added to the list of uncommon manifestations of pediatric Behçet’s disease. Second, infliximab seems to be an effective drug for the management of Behçet’s disease that is refractory to the conventional corticosteroid and immunosuppressive therapy. The selection of optimal dose and frequency of infusion required standardization for our patient.

Informed consent
Written informed consent was obtained from the patient’s legal guardian for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author details
1 Department of Surgery, Ophthalmology Unit, Institute for Maternal and Child Health Burlo Garofolo, Via dell’Istria, 65/1, Trieste I-34100, Italy.
2 Department of Paediatrics, Rheumatology Unit, Institute for Maternal and Child Health Burlo Garofolo, Via dell’Istria, 65/1, Trieste I-34100, Italy.

Authors’ contributions
FP and SP interpreted the ophthalmological manifestation of the disease. FP was also the major contributor in writing the manuscript. LL and IR analyzed the patient data regarding the systemic manifestation of the disease. They also provided support in administering the systemic immunosuppressive and biological therapy. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 12 January 2010 Accepted: 25 February 2011
Published: 25 February 2011

References
1. International Study Group for Behçet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990, 335:1078-1080.
2. Citrik M, Berker N, Songur MS, Soykan E, Zilelioglu O: Ocular findings in childhood-onset Behçet disease. J AAPOS 2009, 13:391-395.
3. Dursun D, Akova Y, Yucel E: Myositis and scleritis associated with Behçet’s disease: an atypical presentation. Ocul Immunol Inflamm 2004, 12:329-332.
4. Sakellarious G, Berberidis C, Vounoumpxida P: A case of Behçet disease with scleromalacia perforans. Rheumatology 2005, 44:258-260.
5. Mitra S, Koul RI: Paediatric neuro-Behçet disease presenting with optic nerve swelling. Br J Ophthalmol 1999, 83:1096-1099.
6. Piptone N, Olivier I, Cantini F, Triolo G, Salvareni C: New approaches in the treatment of Adamantaniades-Behçet’s disease. Curr Opin Rheumatol 2006, 18:3-9.
7. Sayinilp N, Ozcebe OI, Ozdemir O, Haznedarooglu IC, Dundar S, Kirazli S: Cytokines in Behçet’s disease. J Rheumatol 1996, 23:321-322.
8. Sugita S, Yamada Y, Mochizuki M: Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol 2010.

Cite this article as: Parentin et al.: Paediatric Behçet’s disease presenting with recurrent papillitis and episcleritis: a case report. Journal of Medical Case Reports 2011 5:81.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit